Any current/future new fundraising through debt or equity?

There is no specific mention of any current or future fundraising plans through debt or equity in the provided transcript. Net debt increased from INR 967 crores in June 2025 to INR 1,280 crores as of September 30, 2025, primarily due to borrowing to fund working capital and the acquisition of Utility Therapeutics. The management indicated that net debt levels, excluding the Pivya launch, are expected to gradually reduce in FY 2027 with new product launches and growth from new facilities. There was no explicit discussion or guidance about raising additional debt or equity financing during the

Any current/future capex/capital investment/strategic investment?

Alembic Pharmaceuticals has commercialized new injectable and oncology plants over the last two and a half years, currently running below anticipated utilization but with expected ramp-up in H2 FY26 and FY27 due to upcoming product approvals and launches. No specific new capex figures disclosed yet; unabsorbed overheads exist due to investments in new facilities. Investment focus remains on complex and high-value areas such as injectables, peptides (e.g., Mounjaro Tirzepatide), oral solids, and drug discovery with emphasis on early entry opportunities. Recent acquisition of Utility Therapeu

Future growth expectations in earnings/operating earnings/profits/EPS?

Alembic expects continued revenue growth driven by new product launches and geographic expansion, including the US and Rest of World (ROW) markets. EBITDA margin is targeted to improve over the next 2-3 years towards 18-19%, ultimately approaching 20%. Margin expansion is expected through better capacity utilization, especially in injectable and oncology plants. R&D spend will remain controlled around 8% of revenue (~INR 600-650 crores annually) to support complex and high-value product launches without excessive cost burden. The new branded US specialty product launch (Pivya) will impact near

Alembic Pharmaceuticals LtdQ3 FY26Pharmaceuticals & Biotechnology

Alembic Pharmaceuticals Ltd Q3 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹825P/E: 21.6Market Cap: ₹16.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Future growth expectations for Alembic Pharmaceuticals as per the transcript include: - Continued ramp-up of new launches expected to improve sales volumes, especially in the US and Rest of World (ROW) markets. - India business aims to catch up with and potentially outperform market growth soon, with improvements expected from productivity enhancements and stabilized brands like Azithral. - US business growth expected to be sustained by new product launches such as Entresto and Pivya (launch planned in late Q4 FY26), focusing on branded segments. - ROW generics projected to grow at 15-20% annually. - EBITDA margins targeted to improve towards 18-20% over the next couple of years with higher capacity utilization and better operational leverage. - Growth in API business expected at about 10%. - Investments in specialty injectables and peptides to start yielding approvals and revenue in coming quarters. - Animal health, Gynecology, and Ophthalmology segments to continue accelerated performance in India.

Margin guidance

Category 1

→Alembic expects continued revenue growth driven by new product launches and geographic expansion, including the US and Rest of World (ROW) markets.
→EBITDA margin is targeted to improve over the next 2-3 years towards 18-19%, ultimately approaching 20%.
→Margin expansion is expected through better capacity utilization, especially in injectable and oncology plants.
→R&D spend will remain controlled around 8% of revenue (~INR 600-650 crores annually) to support complex and high-value product launches without excessive cost burden.
→The new branded US specialty product launch (Pivya) will impact near-term profitability but is seen as a medium to long-term growth driver.
→The India business is aiming to catch up with and then outperform market growth, with focus on segments like Gynecology, Ophthalmology, and Animal Health.
→Net debt expected to gradually reduce post new product launches and business growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any current or future fundraising plans through debt or equity in the provided transcript.
→Net debt increased from INR 967 crores in June 2025 to INR 1,280 crores as of September 30, 2025, primarily due to borrowing to fund working capital and the acquisition of Utility Therapeutics.
→The management indicated that net debt levels, excluding the Pivya launch, are expected to gradually reduce in FY 2027 with new product launches and growth from new facilities.
→There was no explicit discussion or guidance about raising additional debt or equity financing during the call.

Order book

The transcript from Alembic Pharmaceuticals Limited's Q2 FY26 earnings call does not provide explicit details on the current or expected order book or pending orders. However, the following points can be inferred related to their business outlook and product launches, which impact order flow: - The company expects ramp-up from new product launches, especially in the U.S. generics and specialty segments (e.g., Pivya launch planned for late Q4 FY26). - There are multiple product launches expected in the U.S. in the coming quarters: 4-5 products in Q3 and another 4-5 in Q4 FY26. - New injectable and oncology plants are expected to improve capacity utilization in H2 FY26. - The company mentioned a robust pipeline with 269 cumulative ANDA filings and 226 approvals, indicating a strong pipeline fueling future orders. - India business recovery and market growth improvements are expected in the second half. - No specific quantitative figures on order book or pending orders were disclosed.

Capex plans

Yes

→Alembic Pharmaceuticals has commercialized new injectable and oncology plants over the last two and a half years, currently running below anticipated utilization but with expected ramp-up in H2 FY26 and FY27 due to upcoming product approvals and launches.
→No specific new capex figures disclosed yet; unabsorbed overheads exist due to investments in new facilities.
→Investment focus remains on complex and high-value areas such as injectables, peptides (e.g., Mounjaro Tirzepatide), oral solids, and drug discovery with emphasis on early entry opportunities.
→Recent acquisition of Utility Therapeutics to enter the US branded market with Pivya; involves upfront and milestone payments and profit-sharing, indicating strategic investment in specialty branded segment.
→Gradual ramp-up of the US branded business with investment in building a small field force starting end Q4 FY26, implying ongoing marketing and operational investments.
→Management expects margin improvement with better capacity utilization and growth from new facilities in coming years, targeting EBITDA margin of 18-20% in the next couple of years.

How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alembic Pharmaceuticals Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alembic Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio